Dr. Nilüfer Ertekin-Taner, a renowned physician-scientist and professor at Mayo Clinic, is spearheading a transformative $41 million research program known as CLEAR-AD. This initiative focuses on advancing Alzheimer's research within multiethnic populations, including traditionally understudied groups like African Americans and Latino Americans. The program aims to identify precision medicine biomarkers and therapeutic targets for Alzheimer's by analyzing blood and brain tissue samples. This research is funded by a National Institutes of Health grant and seeks to understand the molecular underpinnings of the disease. Ultimately, it aspires to predict Alzheimer's development, the speed of progression, and discover precision medicine treatments. Collaborating with several institutions, Dr. Ertekin-Taner's work highlights the urgency of addressing Alzheimer's disease and emphasizes inclusivity in medical research.